ATE323680T1 - 7-arylsulfonamid-2,3,4,5-tetrahydro-1h- benzo¬däazepine mit 5-ht6 rezeptor affinität zur behandlung von zentralnervensystemerkrankungen - Google Patents
7-arylsulfonamid-2,3,4,5-tetrahydro-1h- benzo¬däazepine mit 5-ht6 rezeptor affinität zur behandlung von zentralnervensystemerkrankungenInfo
- Publication number
- ATE323680T1 ATE323680T1 AT03704631T AT03704631T ATE323680T1 AT E323680 T1 ATE323680 T1 AT E323680T1 AT 03704631 T AT03704631 T AT 03704631T AT 03704631 T AT03704631 T AT 03704631T AT E323680 T1 ATE323680 T1 AT E323680T1
- Authority
- AT
- Austria
- Prior art keywords
- benzodeazepine
- arylsulfonamid
- tetrahydro
- treatment
- nervous system
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/16—Benzazepines; Hydrogenated benzazepines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0203437A GB0203437D0 (en) | 2002-02-13 | 2002-02-13 | Novel compounds |
| GB0204758A GB0204758D0 (en) | 2002-02-28 | 2002-02-28 | Novel compounds |
| GB0212548A GB0212548D0 (en) | 2002-05-30 | 2002-05-30 | Novel compounds |
| GB0219711A GB0219711D0 (en) | 2002-08-23 | 2002-08-23 | Novel compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE323680T1 true ATE323680T1 (de) | 2006-05-15 |
Family
ID=27739230
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03704631T ATE323680T1 (de) | 2002-02-13 | 2003-02-13 | 7-arylsulfonamid-2,3,4,5-tetrahydro-1h- benzo¬däazepine mit 5-ht6 rezeptor affinität zur behandlung von zentralnervensystemerkrankungen |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20050090485A1 (de) |
| EP (1) | EP1487801B1 (de) |
| JP (1) | JP2005522452A (de) |
| AR (1) | AR038421A1 (de) |
| AT (1) | ATE323680T1 (de) |
| AU (1) | AU2003206909A1 (de) |
| DE (1) | DE60304695T2 (de) |
| ES (1) | ES2260607T3 (de) |
| TW (1) | TW200306843A (de) |
| WO (1) | WO2003068751A1 (de) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20040081201A (ko) * | 2002-02-13 | 2004-09-20 | 글락소 그룹 리미티드 | 항정신병제로서 벤젠술폰아미드 유도체 |
| EP1495004A2 (de) * | 2002-02-13 | 2005-01-12 | Glaxo Group Limited | Benzensulfonamidderivate und deren verwendung als dopamin d2 und d3 rezeptor liganden |
| IL164108A0 (en) * | 2002-03-27 | 2005-12-18 | Glaxo Group Ltd | Quinoline derivatives and their useas 5-ht6 ligands |
| AR040126A1 (es) | 2002-05-29 | 2005-03-16 | Glaxo Group Ltd | Compuesto de fenilsulfonilo, composicion farmaceutica que lo comprende y su uso para la elaboracion de un medicamento |
| RS20060035A (en) | 2003-07-22 | 2008-08-07 | Arena Pharmaceuticals Inc., | Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of disorders related thereto |
| GB0329214D0 (en) * | 2003-12-17 | 2004-01-21 | Glaxo Group Ltd | Novel compounds |
| US20050137186A1 (en) * | 2003-12-18 | 2005-06-23 | Abbott Gmbh & Co. Kg. | Tetrahydrobenzazepines and their use |
| EP1694334B1 (de) * | 2003-12-18 | 2011-10-19 | Abbott GmbH & Co. KG | Tetrahydrobenzazepine und ihre verwendung in der modulation des dopamin-d3-rezeptors |
| PE20060302A1 (es) * | 2004-06-18 | 2006-04-08 | Glaxo Group Ltd | Derivados de benzazepina como antagonistas del receptor h3 |
| US7582673B2 (en) * | 2004-10-21 | 2009-09-01 | High Point Pharmaceuticals, Llc | Bissulfonamide compounds as agonists of GalR1, compositions, and methods of use |
| US20100173890A1 (en) * | 2005-07-05 | 2010-07-08 | Astrazeneca Ab | Compounds, Process for their Preparation, Intermediates, Pharmaceutical Compositions and their use in the Treatment of 5-HT6 Mediated Disorders such as Alzheimer's Disease, Cognitive Disorders, Cognitive Impairment Associated with Schizophrenia, Obesity and Parkinson's Disease |
| WO2007004959A1 (en) * | 2005-07-05 | 2007-01-11 | Astrazeneca Ab | New compounds, process for their preparation, intermediates, pharmaceutical compositions and their use in the treatment of 5-ht6 mediated disorders such as alzheimer's disease, cognitive disorders, cognitive impairment associated with schizophrenia, obesity and parkinson's disease |
| US20100041672A1 (en) * | 2007-03-21 | 2010-02-18 | Glaxo Group Limited | Use of quinoline derivatives in the treatment of pain and irritable bowel syndrome |
| EP2508177A1 (de) | 2007-12-12 | 2012-10-10 | Glaxo Group Limited | Kombinationen mit 3-phenylsulfonyl-8-piperazinyl-1yl-chinolin |
| US20110021538A1 (en) | 2008-04-02 | 2011-01-27 | Arena Pharmaceuticals, Inc. | Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor |
| US9126946B2 (en) | 2008-10-28 | 2015-09-08 | Arena Pharmaceuticals, Inc. | Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto |
| CN103145619A (zh) * | 2012-06-15 | 2013-06-12 | 史慎德 | 7-氯-6-苯磺酰氨基-2,3,4,5-四氢-1H-苯并[d]氮杂*的制备 |
| JP2018516992A (ja) | 2015-06-12 | 2018-06-28 | アクソファント サイエンシーズ ゲーエムベーハーＡｘｏｖａｎｔ Ｓｃｉｅｎｃｅｓ Ｇｍｂｈ | レム睡眠行動障害の予防および処置のために有用なジアリールおよびアリールヘテロアリール尿素誘導体 |
| BR112018000728A2 (pt) | 2015-07-15 | 2018-09-04 | Axovant Sciences Gmbh | resumo método para a profilaxia e/ou tratamento de alucinações visuais em um sujeito com necessidade do mesmo |
| KR102206321B1 (ko) | 2016-01-15 | 2021-01-21 | 화이자 인코포레이티드 | 6,7,8,9-테트라하이드로-5H-피리도[2,3-d]아제핀 도파민 D3 리간드 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3314963A (en) * | 1962-07-23 | 1967-04-18 | Pfizer & Co C | Azabenzocycloalkane-n-carboxamidines |
| DE3614863A1 (de) * | 1986-05-02 | 1987-11-05 | Wabco Westinghouse Fahrzeug | Betaetigungseinrichtung fuer eine differentialsperre mit einem stellglied |
| US4959360A (en) * | 1988-06-01 | 1990-09-25 | Smithkline Beecham Corporation | α-adrenergic receptor antagonists |
| US4978660A (en) * | 1988-06-01 | 1990-12-18 | Smithkline Beecham Corporation | α-adrenergic receptor antagonists |
| US5006521A (en) * | 1988-06-01 | 1991-04-09 | Smithkline Beecham Corporation | α-adrenergic receptor antagonists and methods of use thereas |
| US5939451A (en) * | 1996-06-28 | 1999-08-17 | Hoffmann-La Roche Inc. | Use of sulfonamides |
| DZ2376A1 (fr) * | 1996-12-19 | 2002-12-28 | Smithkline Beecham Plc | Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant. |
| NZ501258A (en) * | 1997-07-11 | 2001-07-27 | Smithkline Beecham P | Benzenesulfonamide compounds with 5HT6 receptor antagonist activity for treating anxiety and/or depression |
| GB9801392D0 (en) * | 1998-01-22 | 1998-03-18 | Smithkline Beecham Plc | Novel compounds |
| GB9803411D0 (en) * | 1998-02-18 | 1998-04-15 | Smithkline Beecham Plc | Novel compounds |
| GB9926302D0 (en) * | 1999-11-05 | 2000-01-12 | Smithkline Beecham Plc | Novel compounds |
| GB0111186D0 (en) * | 2001-05-08 | 2001-06-27 | Smithkline Beecham Plc | Novel compounds |
| EP1495004A2 (de) * | 2002-02-13 | 2005-01-12 | Glaxo Group Limited | Benzensulfonamidderivate und deren verwendung als dopamin d2 und d3 rezeptor liganden |
| KR20040081201A (ko) * | 2002-02-13 | 2004-09-20 | 글락소 그룹 리미티드 | 항정신병제로서 벤젠술폰아미드 유도체 |
-
2003
- 2003-02-13 EP EP03704631A patent/EP1487801B1/de not_active Expired - Lifetime
- 2003-02-13 AT AT03704631T patent/ATE323680T1/de not_active IP Right Cessation
- 2003-02-13 AU AU2003206909A patent/AU2003206909A1/en not_active Abandoned
- 2003-02-13 AR ARP030100475A patent/AR038421A1/es unknown
- 2003-02-13 DE DE60304695T patent/DE60304695T2/de not_active Expired - Fee Related
- 2003-02-13 WO PCT/EP2003/001543 patent/WO2003068751A1/en active IP Right Grant
- 2003-02-13 ES ES03704631T patent/ES2260607T3/es not_active Expired - Lifetime
- 2003-02-13 JP JP2003567882A patent/JP2005522452A/ja active Pending
- 2003-02-13 US US10/503,678 patent/US20050090485A1/en not_active Abandoned
- 2003-02-13 TW TW092102942A patent/TW200306843A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2005522452A (ja) | 2005-07-28 |
| WO2003068751A1 (en) | 2003-08-21 |
| TW200306843A (en) | 2003-12-01 |
| AU2003206909A1 (en) | 2003-09-04 |
| AR038421A1 (es) | 2005-01-12 |
| DE60304695T2 (de) | 2006-09-21 |
| DE60304695D1 (de) | 2006-05-24 |
| ES2260607T3 (es) | 2006-11-01 |
| US20050090485A1 (en) | 2005-04-28 |
| EP1487801A1 (de) | 2004-12-22 |
| EP1487801B1 (de) | 2006-04-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE323680T1 (de) | 7-arylsulfonamid-2,3,4,5-tetrahydro-1h- benzo¬däazepine mit 5-ht6 rezeptor affinität zur behandlung von zentralnervensystemerkrankungen | |
| DE602004020072D1 (de) | 1,2,3,4-tetrasubstituiertes indol zur behandlung von atemwegserkrankungen | |
| DE60325209D1 (de) | Diarylharnstoffderivate, die sich zur behandlung von proteinkinaseabhängigen krankheiten eignen | |
| PT1666462E (pt) | Derivados de n-[1h-indol-5-il]-naftaleno-1-sulfonamida e compostos associados enquanto antagonistas do receptor 5- ht6 de serotonina para o tratamento de distúrbios do sistema nervoso central | |
| NO20030603D0 (no) | Behandling av hyperprolifererende sykdommer med epidermale, vekstfaktorreseptorantagonister | |
| NO20053384L (no) | Benzazepinderivater for behandling av neurologiske forstyrrelser. | |
| HK1152243A1 (en) | Vegf for use in the treatment of central nervous system disorders vegf | |
| EE200100441A (et) | Monoamiinide taasomastamise inhibiitorid kesknärvisüsteemi haiguste raviks | |
| ATE346082T1 (de) | Glucocorticoidrezeptorliganden zur behandlung von stoffwechselstörungen | |
| ATE422498T1 (de) | Tetrahydro-pyrazinoä1,2-aüindole für die behandlung von krankheiten des zentralnervensystems | |
| DE60204466D1 (de) | Integrinhemmer zur behandlung von augenkrankheiten | |
| ATE318604T1 (de) | Neue therapeutische kombinationen aus mirtazapin und antipsychotika, zur behandlung oder prophylaxe von psychotischen störungen | |
| ITRM20040317A1 (it) | Apparecchio per la stimolazione dei muscoli dell'apparato locomotorio. | |
| DE60016047D1 (de) | Dihydrobenzopyrane, dihydrobenzothiopyrane und tetrahydrochinoline zur behandlung cox-2-abhängiger krankheiten | |
| DE69822297D1 (de) | Triptolid-derivate geeignet zur behandlung von autoimmunkrankheiten | |
| AU2002227895A1 (en) | Sulphonamides for the treatment of central nervous system diseases | |
| ATE374197T1 (de) | Indolderivate zur behandlung von erkrankungen des zentralnervensystems | |
| ATE491442T1 (de) | 1-phenyl-2- dimethylaminomethylcyclohexanverbindungen zur therapie von depressiven symptomatiken, schmerz und inkontinenz | |
| ATE230741T1 (de) | 3-tetrahydropyridin-4-yl-indole zur behandlung von psychotischen störungen | |
| ATE256126T1 (de) | 5-heteroatom-alkyl substituierte 3-oxo-pyrido(1,2-a)benzimidazol-4-carboxamid derivate zur behandlung zentral nervöser system störungen | |
| NO20001894L (no) | Anvendelse av TNF-antagonister som medikamenter for behandling av septiske sykdommer | |
| DE60124093D1 (de) | S-methyl-dihydro-ziprasidon zur Behandlung von Augenerkrankungen. | |
| TWI245756B (en) | Improved process for the preparation of 1,3-substituted indenes | |
| ATE378052T1 (de) | Verwendung von galanthamin zur behandlung von krankheitserscheinungen des zentralen nervensystems aufgrund von intoxikationen mit psychotropen substanzen | |
| DE60004473D1 (de) | Verwendung von gaba-b rezeptor liganden zur herstellungen von medikamenten zur behandlung von neurodegenerativen erkrankungen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |